Prognostic of DNA‐synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1–T2, N0–N1, M0 breast cancers: A retrospective multicenter study
Prognostic of DNA‐synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1–T2, N0–N1, M0 breast cancers: A retrospective multicenter study
复制标题
908 例 T1–T2、N0–N1、M0 乳腺癌中 DNA 合成酶活性（胸苷激酶和胸苷酸合酶）的预后：一项回顾性多中心研究
DOI：
--
复制
发表时间：
2000
影响因子：
6.4
通讯作者：
P. Martin
中科院分区：
文献类型：
--
作者：
S. Romain;F. Spyratos;F. Descôtes;A. Daver;Béatrice Rostaing‐Puissant;P. Bougnoux;M. Colonna;M. Bolla;P. Martin
在肿瘤增殖的方法学方法中，胸苷激酶（TK）和胸苷酸合成酶（TS）测定考虑了嘧啶合成的特定途径。指出TK和TS在乳腺癌中的预后价值的研究涉及少数患者。我们在一项大型回顾性多中心研究中调查了这些酶及其组合的预后价值。对908份T1 T2、N 0 N1、M0原发性乳腺癌样本进行了检测（中位随访68个月）。采用标准化放射酶法测定细胞液中的TK和TS。虽然TK和TS之间存在正相关（p<10−5），但在某些肿瘤中观察到了较大的差异。两种酶的高水平与肿瘤尺寸大、组织学III级和类固醇受体阴性肿瘤相关。单变量分析显示，TK、TS及其组合可预测不良无转移（MFS）（p < 10−4; p=0.004; p < 10−4）和无病生存（DFS）（p < 10−4; p=0.007; p=0.0001）。在考克斯分析中选择TK作为MFS的独立因素。这是在淋巴结阴性患者中选择的唯一变量。确定了具有特定结局和可能的治疗意义的亚组：a）在未接受辅助治疗的淋巴结阴性患者中，第4四分位数的TK值与MFS较差相关（p=0.0002）和DFS（p=0.0005）与其他四分位数相比; B）在接受辅助化疗的淋巴结阳性患者中，低水平的TK和TS与最高的生存率相关（MFS：p=0.04; DFS：p=0.03）。Int. J. Cancer 87：860-868，2000.© 2000 Wiley利斯公司
Among the methodological approaches of tumor proliferation, thymidine kinase (TK) and thymidylate synthase (TS) assays take into account the specific pathways of pyrimidine synthesis. Studies pointing to a prognostic value of TK and TS in breast cancer involved small numbers of patients. We investigated the prognostic value of these enzymes and their combination in a large retrospective multicenter study. Nine hundred eight T1T2, N0N1, M0 primary breast cancer samples (median follow‐up 68 months) were tested. TK and TS were measured in cytosols by using standardized radioenzymatic methods. Although a positive correlation was obtained between TK and TS (p<10−5), major discrepancies were observed in some tumors. High levels of both enzymes were associated with large tumor size, histological grade III and steroid receptor‐negative tumors. Univariate analysis showed that TK, TS and their combination were predictive of poor metastasis‐free (MFS) (p < 10−4; p=0.004; p < 10−4) and disease‐free survival (DFS) (p < 10−4; p=0.007; p=0.0001). TK was selected as an independent factor for MFS in Cox analysis. It was the only variable selected in node‐negative patients. Subgroups with specific outcomes, with possible therapeutic implications, were identified: a) in node‐negative patients not receiving adjuvant treatment, TK values in the 4th quartile were associated with poor MFS (p=0.0002) and DFS (p=0.0005) as compared to the other quartiles; b) in node‐positive patients receiving adjuvant chemotherapy, low levels of both TK and TS were associated with the highest survival rates (MFS: p=0.04; DFS: p=0.03). Int. J. Cancer 87:860–868, 2000. © 2000 Wiley‐Liss, Inc.
DOI：
--
发表时间：
1996-03
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Richard W. Brown;C. Allred;G. Clark;C. Osborne;S. Hilsenbeck
通讯作者：
Richard W. Brown;C. Allred;G. Clark;C. Osborne;S. Hilsenbeck
DOI：
10.1053/ejso.1999.0657
发表时间：
1999-08-01
期刊：
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
影响因子：
--
作者：
Clahsen, PC;van de Velde, CJH;van de Vijver, MJ
通讯作者：
van de Vijver, MJ
影响因子：
45.3
作者：
Thor, AD;Liu, SQ;Edgerton, SM
通讯作者：
Edgerton, SM